title: Pioglitazone elicits long-term improvements in insulin sensitivity in patients with type 2 diabetes: comparisons with gliclazide-based regimens.
abstract: OBJECTIVE
  Recent studies have demonstrated that pioglitazone (PIO) has beneficial effects on insulin sensitivity compared with placebo in patients with type 2 diabetes. The effects of PIO and gliclazide (GLIC)-based therapy on insulin sensitivity have not previously been directly compared. This analysis aimed to compare the effects of 52 weeks of treatment with PIO (30-45 mg/day) and GLIC (80-320 mg/day), both titrated to maximum tolerable doses, as monotherapy or in combination with metformin (MET), on insulin sensitivity and lipid parameters known to be related to insulin sensitivity in patients with type 2 diabetes.
  
  
  METHODS
  We performed an analysis of 1,880 patients with inadequately controlled type 2 diabetes (HbA1c 7.5-11.0%) who were participants in two parallel-group, double-blind, double-dummy, randomised, multicentre, clinical trials. Measures of insulin sensitivity and lipids were assessed.
  
  
  RESULTS
  The PIO- and GLIC-based regimens produced similar levels of glycaemic control (HbA1c). In both trials, insulin sensitivity as assessed using the homeostasis model assessment was improved in patients receiving PIO, but decreased in those receiving GLIC (mean change, baseline to endpoint: PIO 15.5, GLIC -15.6; p<0.001 and PIO+MET 18.9, GLIC+MET -5.3; p<0.001). Improvements in the atherogenic index of plasma (mean change: PIO -0.17, GLIC -0.08; p<0.001 and PIO+MET -0.17, GLIC+MET -0.02; p<0.001), triglycerides (mean change, mmol/l: PIO+MET -0.62, GLIC+MET -0.22; p<0.001) and NEFA (mean change, mmol/l: PIO+MET -0.12, GLIC+MET-0.05; p<0.001) were greater in PIO-treated patients than in patients receiving GLIC.
  
  
  CONCLUSIONS
  The PIO-based regimens resulted in improved insulin sensitivity and more favourable insulin sensitivity-related lipid profiles compared with the GLIC-based regimens. These benefits may be important in the management of cardiovascular risk in patients with type 2 diabetes.
authors.affiliation: Endocrinology Clinic, Hotel Dieu Hospital, Nantes, France.
authors.forename: B
authors.initials: B
authors.lastname: Charbonnel
authors.forename: M
authors.initials: M
authors.lastname: Roden
authors.forename: R
authors.initials: R
authors.lastname: Urquhart
authors.forename: S
authors.initials: S
authors.lastname: Mariz
authors.forename: D
authors.initials: D
authors.lastname: Johns
authors.forename: M
authors.initials: M
authors.lastname: Mihm
authors.forename: M
authors.initials: M
authors.lastname: Widel
authors.forename: M
authors.initials: M
authors.lastname: Tan
mesh_terms: D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism*; D015992:Body Mass Index; D001835:Body Weight / Q000187:drug effects; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D005907:Gliclazide / Q000627:therapeutic use*; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007328:Insulin / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D000077205:Pioglitazone; D045162:Thiazolidinediones / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D001786:Blood Glucose; D005907:Gliclazide; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin; D000077205:Pioglitazone; D045162:Thiazolidinediones
references.citation: Diabetes. 1997 Jun;46(6):983-8
references.pmid: 9166669
references.citation: Diabetes Care. 2001 May;24(5):933-41
references.pmid: 11347757
references.citation: Clin Chem. 2003 Nov;49(11):1873-80
references.pmid: 14578319
references.citation: Diabetes Res Clin Pract. 1991;14 Suppl 2:S21-36
references.pmid: 1794262
references.citation: J Clin Endocrinol Metab. 2003 Apr;88(4):1637-45
references.pmid: 12679450
references.citation: Diabet Med. 2004 Jun;21(6):568-76
references.pmid: 15154941
references.citation: Atherosclerosis. 1996 Jan 26;119(2):235-45
references.pmid: 8808500
references.citation: J Clin Endocrinol Metab. 2004 Mar;89(3):1481-4
references.pmid: 15001651
references.citation: Diabetes Care. 2003 Sep;26(9):2588-94
references.pmid: 12941723
references.citation: J Clin Endocrinol Metab. 2001 Nov;86(11):5412-9
references.pmid: 11701715
references.citation: Pharmacol Ther. 2002 Jul;95(1):47-62
references.pmid: 12163127
references.citation: Diabetes Care. 2004 Jun;27(6):1487-95
references.pmid: 15161807
references.citation: Diabetes Care. 1998 Dec;21(12):2191-2
references.pmid: 9839117
references.citation: Diabetes. 1999 Sep;48(9):1836-41
references.pmid: 10480616
references.citation: Diabetologia. 2000 Feb;43(2):148-55
references.pmid: 10753035
references.citation: Lancet. 1998 Sep 12;352(9131):837-53
references.pmid: 9742976
references.citation: Clin Biochem. 2001 Oct;34(7):583-8
references.pmid: 11738396
references.citation: Diabetes Care. 2001 Apr;24(4):710-9
references.pmid: 11315836
references.citation: Arch Intern Med. 2001 Dec 10-24;161(22):2685-92
references.pmid: 11732933
references.citation: Diabet Med. 1998 Apr;15(4):297-303
references.pmid: 9585394
references.citation: BMJ. 1998 Mar 14;316(7134):823-8
references.pmid: 9549452
references.citation: Diabetes Metab Res Rev. 2005 Mar-Apr;21(2):167-74
references.pmid: 15386821
references.citation: JAMA. 2001 May 16;285(19):2486-97
references.pmid: 11368702
references.citation: J Clin Endocrinol Metab. 2000 Jul;85(7):2402-10
references.pmid: 10902785
references.citation: Circulation. 1996 Jan 1;93(1):54-9
references.pmid: 8616941
references.citation: Clin Ther. 2003 Apr;25(4):1074-95
references.pmid: 12809958
references.citation: Clin Chem. 2004 Jul;50(7):1184-8
references.pmid: 15117857
references.citation: Am J Cardiol. 1995 Jun 15;75(17):1189-95
references.pmid: 7778537
references.citation: Circulation. 1998 Mar 17;97(10):996-1001
references.pmid: 9529268
references.citation: Metabolism. 1984 Jan;33(1):68-75
references.pmid: 6361449
references.citation: Diabetes Care. 2002 Jul;25(7):1135-41
references.pmid: 12087010
references.citation: Diabetes Care. 2000 Jan;23(1):57-63
references.pmid: 10857969
references.citation: J Clin Endocrinol Metab. 2002 Jun;87(6):2784-91
references.pmid: 12050251
references.citation: J Clin Invest. 1996 Jun 15;97(12):2859-65
references.pmid: 8675698
references.citation: Circulation. 1996 May 15;93(10):1809-17
references.pmid: 8635260
references.citation: Diabetes. 1999 Aug;48(8):1600-6
references.pmid: 10426379
references.citation: Diabetes Care. 2003 Aug;26(8):2426-32
references.pmid: 12882874
references.citation: Diabetes. 1999 Feb;48(2):358-64
references.pmid: 10334314
references.citation: Diabetologia. 1999 Jan;42(1):113-6
references.pmid: 10027589
references.citation: Diabetes Care. 2004 Jul;27(7):1647-53
references.pmid: 15220241
references.citation: Diabet Med. 2005 Apr;22(4):399-405
references.pmid: 15787663